메뉴 건너뛰기




Volumn 23, Issue 3, 2013, Pages 201-207

Castrate-resistant prostate cancer: Postdocetaxel management

Author keywords

castrate resistant prostate cancer; chemotherapy; docetaxel; hormonal therapy

Indexed keywords

ABIRATERONE; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DOCETAXEL; ENZALUTAMIDE; KETOCONAZOLE; MITOXANTRONE; ORTERONEL; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T;

EID: 84876411304     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835e2253     Document Type: Review
Times cited : (7)

References (42)
  • 3
    • 79957953692 scopus 로고    scopus 로고
    • Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
    • Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29:2191-2198.
    • (2011) J Clin Oncol , vol.29 , pp. 2191-2198
    • Scher, H.I.1    Jia, X.2    Chi, K.3
  • 4
    • 84861690508 scopus 로고    scopus 로고
    • Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    • Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534-1540.
    • (2012) J Clin Oncol , vol.30 , pp. 1534-1540
    • Kelly, W.K.1    Halabi, S.2    Carducci, M.3
  • 6
    • 58149347705 scopus 로고    scopus 로고
    • Microtubule active agents: Beyond the taxane frontier
    • Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-7172.
    • (2008) Clin Cancer Res , vol.14 , pp. 7167-7172
    • Morris, P.G.1    Fornier, M.N.2
  • 8
    • 59449102526 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors
    • Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-730.
    • (2009) Clin Cancer Res , vol.15 , pp. 723-730
    • Mita, A.C.1    Denis, L.J.2    Rowinsky, E.K.3
  • 9
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 12
    • 0027487289 scopus 로고
    • Importance of continued testicular suppression in hormone-refractory prostate cancer
    • Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:2167- 2172. (Pubitemid 23332253)
    • (1993) Journal of Clinical Oncology , vol.11 , Issue.11 , pp. 2167-2172
    • Taylor, C.D.1    Elson, P.2    Trump, D.L.3
  • 14
    • 33644675811 scopus 로고    scopus 로고
    • Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
    • DOI 10.1200/JCO.2005.03.4777
    • Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261. (Pubitemid 46211563)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.32 , pp. 8253-8261
    • Scher, H.I.1    Sawyers, C.L.2
  • 15
    • 84864003814 scopus 로고    scopus 로고
    • Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
    • Eichholz A, Ferraldeschi R, Attard G, de Bono JS. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360:68-75.
    • (2012) Mol Cell Endocrinol , vol.360 , pp. 68-75
    • Eichholz, A.1    Ferraldeschi, R.2    Attard, G.3    De Bono, J.S.4
  • 18
    • 49249119358 scopus 로고    scopus 로고
    • Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
    • Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
    • (2008) Cancer Res , vol.68 , pp. 4447-4454
    • Montgomery, R.B.1    Mostaghel, E.A.2    Vessella, R.3
  • 19
    • 0029058770 scopus 로고
    • Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer
    • Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38:2463-2471.
    • (1995) J Med Chem , vol.38 , pp. 2463-2471
    • Potter, G.A.1    Barrie, S.E.2    Jarman, M.3    Rowlands, M.G.4
  • 20
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005. The results of this clinical trial revealed abiraterone with prednisone to have a survival benefit over placebo and prednisone in a postdocetaxel mCRPC patient population, leading to the FDA approval of abiraterone in the USA.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 21
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148. The results of this clinical trial demonstrated abiraterone plus predisone improves overall survival in chemotherapy-nai?ve patients with CPRC, leading to FDA approval of expanded indication for abiraterone.
    • N Engl J Med , vol.2013 , Issue.368 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 22
    • 65649090203 scopus 로고    scopus 로고
    • Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    • Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
    • (2009) Science , vol.324 , pp. 787-790
    • Tran, C.1    Ouk, S.2    Clegg, N.J.3
  • 23
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
    • (2010) Lancet , vol.375 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 24
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197. The results of this clinical trial revealed a survival benefit of enzalutamide over placebo in patients with postdocetaxel mCRPC, leading to the recent FDA approval of enzalutamide in the USA.
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 25
    • 77956235472 scopus 로고    scopus 로고
    • Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
    • Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 2010; 16:4319-4324.
    • (2010) Clin Cancer Res , vol.16 , pp. 4319-4324
    • Yamaoka, M.1    Hara, T.2    Kusaka, M.3
  • 26
    • 84860870765 scopus 로고    scopus 로고
    • Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration- resistant prostate cancer: Updated data from a phase I/II study
    • abstr 98
    • Agus DB, Stadler MW, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration- resistant prostate cancer: updated data from a phase I/II study. J Clin Oncol 2012; 30 (Suppl. 5):abstr. 98.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 5
    • Agus, D.B.1    Stadler, M.W.2    Shevrin, D.H.3
  • 27
    • 80054021222 scopus 로고    scopus 로고
    • Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
    • Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71:6503-6513.
    • (2011) Cancer Res , vol.71 , pp. 6503-6513
    • Cai, C.1    Chen, S.2    Ng, P.3
  • 28
    • 84863013857 scopus 로고    scopus 로고
    • Modeling a lethal prostate cancer variant with small-cell carcinoma features
    • Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18:666-677.
    • (2012) Clin Cancer Res , vol.18 , pp. 666-677
    • Tzelepi, V.1    Zhang, J.2    Lu, J.F.3
  • 29
    • 80052827038 scopus 로고    scopus 로고
    • Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants
    • Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17:5913-5925.
    • (2011) Clin Cancer Res , vol.17 , pp. 5913-5925
    • Mostaghel, E.A.1    Marck, B.T.2    Plymate, S.R.3
  • 30
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
    • Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822.
    • (2011) Lancet , vol.377 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3
  • 31
    • 0037009822 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 33
    • 0025781809 scopus 로고
    • A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
    • Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954-958.
    • (1991) Eur J Cancer , vol.27 , pp. 954-958
    • Lewington, V.J.1    McEwan, A.J.2    Ackery, D.M.3
  • 34
    • 84860854128 scopus 로고    scopus 로고
    • Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castrationresistant prostate cancer with bone metastases
    • abstr 8
    • Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castrationresistant prostate cancer with bone metastases. J Clin Oncol 2012; 30 (Suppl. 5):abstr. 8. The results of this clinical trial [34 &, 35 & ] demonstrated significant survival benefit, at an interim analysis, along with pain palliation and excellent safety profile, based on which radium-223 chloride was granted Fast Track designation by the FDA.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 5
    • Parker, C.1    Heinrich, D.2    O'Sullivan, J.M.3
  • 35
    • 84865834363 scopus 로고    scopus 로고
    • Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer patients with bone metastases (ALSYMPCA)
    • Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer patients with bone metastases (ALSYMPCA). J Clin Oncol 2012; 30 (Suppl.):LBA4512. The results of this clinical trial [34 &, 35 & ] demonstrated significant survival benefit, at an interim analysis, along with pain palliation and excellent safety profile, based on which radium-223 chloride was granted Fast Track designation by the FDA.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 36
    • 68549135290 scopus 로고    scopus 로고
    • Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
    • Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-3679.
    • (2009) Cancer , vol.115 , pp. 3670-3679
    • Higano, C.S.1    Schellhammer, P.F.2    Small, E.J.3
  • 37
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 38
    • 84866562665 scopus 로고    scopus 로고
    • Prostate cancer, version 3.2012: Featured updates to the NCCN guidelines
    • Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 2012; 10:1081-1087.
    • (2012) J Natl Compr Cancer Netw , vol.10 , pp. 1081-1087
    • Mohler, J.L.1    Armstrong, A.J.2    Bahnson, R.R.3
  • 39
    • 80053571555 scopus 로고    scopus 로고
    • Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: Results from a phase II randomized discontinuation trial
    • abstr 4516
    • Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29(Suppl.):abstr. 4516.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Hussain, M.1    Smith, M.R.2    Sweeney, C.3
  • 40
    • 84905170852 scopus 로고    scopus 로고
    • Cabozantinib (XL184) in chemotherapy- pretreated metastatic castration resistant prostate cancer: Results from a phase II nonrandomized expansion cohort
    • abstr 4513
    • Smith MR, Sweeney C, Rathkopf DE, et al. Cabozantinib (XL184) in chemotherapy- pretreated metastatic castration resistant prostate cancer: results from a phase II nonrandomized expansion cohort. J Clin Oncol 2012; 30 (Suppl.):abstr. 4513.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Smith, M.R.1    Sweeney, C.2    De, R.3
  • 41
    • 77957957234 scopus 로고    scopus 로고
    • Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer
    • Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28:4247-4254.
    • (2010) J Clin Oncol , vol.28 , pp. 4247-4254
    • Chi, K.N.1    Hotte, S.J.2    Yu, E.Y.3
  • 42
    • 80052468423 scopus 로고    scopus 로고
    • Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    • Saad F, Hotte S, North S, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011; 17:5765-5773.
    • (2011) Clin Cancer Res , vol.17 , pp. 5765-5773
    • Saad, F.1    Hotte, S.2    North, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.